CWA
NRXP icon

Carolina Wealth Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Carolina Wealth Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$165 – 283
2025
Q3 		$165 Hold
50
– – ﹤0.01% 225
2025
Q2 		$163 Hold
50
– – ﹤0.01% 260
2025
Q1 		$103 Hold
50
– – ﹤0.01% 279
2024
Q4 		$110 Buy
+50
New +$67 ﹤0.01% 291

Other funds holding NRXP

AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Carolina Wealth Advisors's NRXP Position: Q4 2025 in Review

Carolina Wealth Advisors sold out of NRX Pharmaceuticals (NRXP) in Q4 2025, closing a stake of 50 shares — an estimated $165 sold.

Carolina Wealth Advisors first reported a position in NRXP in Q4 2024 and held it in 4 quarters. The position peaked at $165 in Q3 2025. 28 funds tracked by Wall St. Rank hold NRXP as of Q4 2025.

  • Carolina Wealth Advisors reported no remaining NRX Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Carolina Wealth Advisors sold 50 NRX Pharmaceuticals shares in Q4 2025, an estimated $165.
  • Carolina Wealth Advisors first reported a position in NRX Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Carolina Wealth Advisors's NRX Pharmaceuticals position peaked at $165 in Q3 2025.
  • 28 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2025.

Based on Carolina Wealth Advisors's 13F filing for Q4 2025, filed 21 Jan 2026.